Dashboard
With a fall in Net Sales of -20.82%, the company declared Very Negative results in Jun 25
- PRE-TAX PROFIT(Q) At USD -1.76 MM has Fallen at -180.33%
- NET PROFIT(Q) At USD -1.04 MM has Fallen at -164.33%
- ROCE(HY) Lowest at -1.62%
Risky - Market Cap of less than 100 cr
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 53 Million (Micro Cap)
45.00
NA
0.00%
-0.42
-1.63%
1.02
Total Returns (Price + Dividend) 
Sensus Healthcare, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
Is Sensus Healthcare, Inc. technically bullish or bearish?
As of 8 August 2025, the technical trend for Sensus Healthcare, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators. The MACD is bearish on both the weekly and monthly time frames, and Bollinger Bands also confirm a bearish outlook for both periods. Daily moving averages are bearish, and the KST is bearish on the weekly and mildly bearish on the monthly. The Dow Theory shows a mildly bullish signal on the weekly but no trend on the monthly, while the OBV is mildly bearish on the weekly. There is no available return data to compare the company's performance against the S&P 500....
Read MoreIs Sensus Healthcare, Inc. overvalued or undervalued?
As of 7 August 2025, the valuation grade for Sensus Healthcare, Inc. has moved from expensive to risky, indicating a shift in perception regarding its market position. The company appears to be overvalued, given its high P/E ratio of 45 compared to peers and industry standards. Additionally, the EV to EBITDA ratio stands at 20.70, which is significantly higher than Kewaunee Scientific Corp.'s attractive EV to EBITDA of 8.2820, further emphasizing the relative overvaluation of Sensus. With a ROCE of 7.47% and a ROE of 3.40%, Sensus Healthcare's financial performance does not justify its current valuation metrics. The peer comparison shows that while Sensus is categorized as risky, other companies like Kewaunee Scientific Corp. are considered attractive, highlighting the disparity in valuation. Although return data is not available for a direct comparison with the S&P 500, the current valuation metrics sugge...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 12 Schemes (10.19%)
Held by 17 Foreign Institutions (2.51%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is -20.65% vs 104.44% in Jun 2024
YoY Growth in quarter ended Jun 2025 is -162.50% vs 500.00% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 71.31% vs -45.17% in Dec 2023
YoY Growth in year ended Dec 2024 is 1,220.00% vs -97.93% in Dec 2023






